Genetic engineers can design and assemble sophisticated gene circuits to program cells with new functions, but important signaling molecules can become diluted as these cells grow and divide, causing ...
The drilling rate of penetration (ROP) is essential in the oil and gas industry, influencing both efficiency and cost-effectiveness. Traditional methods, anchored in empirical correlations and basic ...
Uniqure NV is regrouping after a surprise switcheroo by the havoc-beset U.S. FDA regarding phase I/II studies with AMT-130 vs. external control in Huntington’s disease (HD) – news of which pushed down ...
AI-powered vector design and preclinical validation mark the first step in a multi-phase program aimed at accelerating the path from discovery to clinical assessment in Alzheimer's disease. AUSTIN, TX ...
LOS ANGELES--(BUSINESS WIRE)--Rarity PBC, a Public Benefit Corporation dedicated to expanding the availability of transformative gene therapies for rare diseases, today announced the closing of a $4.6 ...
Shares of Pitney Bowes (PBI) were little changed in extended trading Wednesday after the company reported third-quarter results that came in line with Wall Street expectations for both profit and ...
STAMFORD, Conn. (AP) — STAMFORD, Conn. (AP) — Pitney Bowes Inc. (PBI) on Wednesday reported earnings of $52 million in its third quarter. On a per-share basis, the Stamford, Connecticut-based company ...
Shortly after taking the reins at BioMarin, CEO Alexander Hardy laid out three paths the company could take for its struggling hemophilia A gene therapy, Roctavian. A year after opting to shrink the ...
NEW YORK – BioMarin on Monday said it is "pursuing options" to divest its hemophilia A gene therapy Roctavian (valoctocogene roxaparvovec), including exploring out-licensing opportunities. The update, ...
BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending competition for achondroplasia therapy Voxzogo and the divestment of the gene ...
Oct 27 (Reuters) - BioMarin Pharmaceutical (BMRN.O), opens new tab said on Monday it plans to divest its gene therapy, a product once expected to be a blockbuster treatment for a type of rare bleeding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback